- 作者：Reiko Imai ; MD ; PhD&lowast ; ; r_imai@nirs.go.jp" class="auth_mail" title="E-mail the corresponding author ; Tadashi Kamada ; MD ; PhD&lowast ; ; Nobuhito Araki ; MD ; PhD&dagger ; ; Working Group for Bone ; Soft Tissue SarcomasSatoshi Abe ; Yukihide Iwamoto ; Toshifumi Ozaki ; Chihiro Kanehira ; Mitsunori Kaya ; Kazuhisa Takahashi ; Hirokazu Chuman ; Hirohiko Tsujii ; Masazumi Tsuneyoshi ; Yoshihiro Nishida ; Hiroaki Hiraga ; Toru Hiruma ; Rikuo Machinami ; Akihiko Matsumine ; Seiichi Matsumoto ; Hideo Morioka ; Takehiko Yamaguchi ; Tsukasa Yonemoto
- 刊名：International Journal of Radiation Oncology*Biology*Physics
- 出版年：2016
- 出版时间：1 May 2016
- 年：2016
- 卷：95
- 期：1
- 页码：322-327
- 全文大小：607 K
Patients and Methods
One hundred eighty-eight patients were treated with carbon ion radiation therapy at a single institute between 1996 and 2013 and retrospectively analyzed. The median age was 66 years. The highest proximal invasion reached past S2 level in 137 patients. The median clinical target volume was 345 cm3. One hundred six patients received 67.2 gray equivalents (GyE)/16 fractions (fr), 74 patients received 70.4 GyE/16 fr, 7 patients received 73.6 GyE/16 fr, and 1 patient received 64.0 GyE/16 fr.
Results
The median follow-up period was 62 months (range, 6.8-147.5 months). Seventy percent of patients were followed for 5 years or until death. The 5-year local control, overall survival, and disease-free survival rates were 77.2%, 81.1%, and 50.3%, respectively. Forty-one patients had a local recurrence. Sex, tumor volume, level of proximal invasion, and irradiated dose were unrelated to local control. There was grade 3 toxicity of the peripheral nerves in 6 patients and grade 4 toxicity of the skin in 2 patients. Ambulation remained in 97% of patients.
Conclusions
Carbon ion radiation therapy was safe and effective for unresectable chordoma and provided good local control and survival while preserving ambulation.